Steroid bill excludes AERs
This article was originally published in The Tan Sheet
Executive Summary
Senate Judiciary Committee approves the Anabolic Steroid Control Act (S 2195) Sept. 30 without language establishing mandatory adverse event reporting for supplements urged by Sen. Richard Durbin (D-Ill.). Durbin and committee Chair Orrin Hatch (R-Utah) agreed in June to work together to develop AER legislation with input from industry and other stakeholders. Hatch noted at the time the steroid bill could serve as a vehicle for AER language (1"The Tan Sheet" June 28, 2004, p. 3). According to staffers, the senators have worked out language which is likely to appear in a separate bill. Steroid control bill, which would ban androstenedione and a number of other steroid precursors, retains a controversial exemption for dehydroepiandrosterone (DHEA), along with estrogens and corticosteroids. The House passed a version of the bill in June (2"The Tan Sheet" June 7, 2004, p. 13)...
Senate Judiciary Committee approves the Anabolic Steroid Control Act (S 2195) Sept. 30 without language establishing mandatory adverse event reporting for supplements urged by Sen. Richard Durbin (D-Ill.). Durbin and committee Chair Orrin Hatch (R-Utah) agreed in June to work together to develop AER legislation with input from industry and other stakeholders. Hatch noted at the time the steroid bill could serve as a vehicle for AER language (1 (Also see "Senators Durbin, Hatch To Work Together On AER Plan" - Pink Sheet, 28 Jun, 2004.), p. 3). According to staffers, the senators have worked out language which is likely to appear in a separate bill. Steroid control bill, which would ban androstenedione and a number of other steroid precursors, retains a controversial exemption for dehydroepiandrosterone (DHEA), along with estrogens and corticosteroids. The House passed a version of the bill in June (2 (Also see "Anabolic Steroid Act Heads To Senate After Clearing House 408-3" - Pink Sheet, 7 Jun, 2004.), p. 13).... |